Summary

The 7 major chronic pain markets reached a value of US$ 21.2 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 28.9 Billion by 2034, exhibiting a growth rate (CAGR) of 2.9% during ​2024-2034​.

The chronic pain market has been comprehensively analyzed in IMARC’s new report titled “Chronic Pain Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034”. Chronic pain is long-standing pain that lasts beyond the usual recovery period or coexists with a chronic health condition. Inflammation or damaged nerves can both contribute to the pain. It is also caused by a disease or injury but is considered a separate condition, along with its medical definition and taxonomy. Chronic pain syndrome affects both the physical and mental health of patients. While the pain can be near-constant, there might be flares or intense pain as a result of an increase in stress or activity. The symptoms include joint pain, muscle aches, burning pain, fatigue, sleep problems, loss of stamina or flexibility due to decreased activity, etc. Chronic pain is hard to diagnose and is considered subjective; therefore, only the individual experiencing it can identify and describe it. The diagnosis is usually made by physically examining the body of the patient and performing tests that can assess the cause of the pain. It includes blood tests, electromyography to test muscular activity, imaging tests such as X-rays and MRIs, spinal fluid tests, etc.

The rising prevalence of chronic diseases, such as osteoarthritis, diabetic neuropathy, multiple sclerosis, cancer, etc., is primarily driving the chronic pain market. In addition to this, the expanding geriatric population, who are more susceptible to developing such ailments, is further bolstering the market growth. Moreover, the escalating need for over-the-counter medications and the strong networking of retail pharmacies are also acting as significant growth-inducing factors. Besides this, the emerging popularity of alternative pain relief therapies owing to the escalating awareness regarding the potential implication of prolonged use of pain treatment drugs, including the risk of addiction and other side effects, is further catalyzing the global market. Furthermore, the inflating requirement to reduce the demand-supply gap for effective neuropathic pain management drugs is encouraging the key players to develop innovative and advanced therapies, which is also stimulating the market growth. Apart from this, several pharmaceutical companies are investing in R&D activities to introduce analgesics or painkillers that are more effective, economically viable, and easier to administer. This, in turn, is further creating a positive outlook for the market. Additionally, the rising emphasis on improving medications to simplify treatments and reduce adverse effects, especially for the elderly and pediatric population, is expected to fuel the chronic pain market in the coming years.

IMARC Group’s new report provides an exhaustive analysis of the chronic pain market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic pain and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic pain market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: ​2024-2034​

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic pain market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic pain market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic pain marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the chronic pain market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic pain market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic pain market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the size of the chronic pain patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (​2024-2034​) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic pain?
What will be the growth rate of patients across the seven major markets?

Chronic Pain: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic pain drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic pain market?

ページTOPに戻る

Table of Contents

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Chronic Pain - Introduction
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (​2024-2034​)
4.3 Market Overview (2018-2023) and Forecast (​2024-2034​)
4.4 Competitive Intelligence

5 Chronic Pain - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Chronic Pain - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (​2024-2034​)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (​2024-2034​)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (​2024-2034​)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (​2024-2034​)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (​2024-2034​)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (​2024-2034​)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (​2024-2034​)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (​2024-2034​)

8 Chronic Pain - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm

9 Chronic Pain - Unmet Needs

10 Chronic Pain - Key Endpoints of Treatment

11 Chronic Pain - Marketed Products
11.1 List of Chronic Pain Marketed Drugs Across the Top 7 Markets
11.1.1 Avinza (Morphine Sulfate) - Pfizer
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Belbuca (buprenorphine) – Biodelivery Sciences
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Movantik (naloxegol) - Astrazeneca
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Targiniq ER (oxycodone hyrdocholride+naloxone hydrochloride) – Purdue Pharma

11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Troxyca ER (oxycodone+naltrexone) - Pfizer
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.

12 Chronic Pain - Pipeline Drugs
12.1 List of Chronic Pain Pipeline Drugs Across the Top 7 Markets
12.1.1 Cebranopadol - Tris Pharma
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 LY3852710 - Eli Lilly and Company
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 MEDI0618 - AstraZeneca
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 CAM2038 - Braeburn Pharmaceuticals
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 Dronabinol - Vertanical GmbH
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.

13. Chronic Pain - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Chronic Pain - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Chronic Pain - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (​2024-2034​)
14.2.2 Chronic Pain - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (​2024-2034​)
14.3 Market Scenario - United States
14.3.1 Chronic Pain - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (​2024-2034​)
14.3.2 Chronic Pain - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (​2024-2034​)
14.3.3 Chronic Pain - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Chronic Pain - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (​2024-2034​)
14.4.2 Chronic Pain - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (​2024-2034​)
14.4.3 Chronic Pain - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Chronic Pain - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (​2024-2034​)
14.5.2 Chronic Pain - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (​2024-2034​)
14.5.3 Chronic Pain - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Chronic Pain - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (​2024-2034​)
14.6.2 Chronic Pain - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (​2024-2034​)
14.6.3 Chronic Pain - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Chronic Pain - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (​2024-2034​)
14.7.2 Chronic Pain - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (​2024-2034​)
14.7.3 Chronic Pain - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Chronic Pain - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (​2024-2034​)
14.8.2 Chronic Pain - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (​2024-2034​)
14.8.3 Chronic Pain - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Chronic Pain - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (​2024-2034​)
14.9.2 Chronic Pain - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (​2024-2034​)
14.9.3 Chronic Pain - Access and Reimbursement Overview

15 Chronic Pain - Recent Events and Inputs From Key Opinion Leaders

16 Chronic Pain Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats

17 Appendix